Amai Proteins
Tracked across 2 events · 12 articles · First seen Jun 08, 2026 · Last active Aug 31, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Tech
Impact: Amai Proteins announced the publication of the world's first clinical study on sweet proteins, confirming the safety and metabolic neutrality of its product, Jan Pieterszoon Sweelinck. This milestone strengthens its commercial credibility and accelerates market adoption.
Jun 08, 2026 · 6 articles
Regulatory
Impact: Amai Proteins is the developer of sweelin and the primary beneficiary of the Israeli approval, which expands its commercial reach and validates its technology. This third regulatory clearance in six months strengthens its market position and growth prospects.
Jul 20, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Amai Proteins live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard